First, is Pfizer’s distinction between its “limited” viral mutation experiments and “gain of function” or “directed evolution” research—the kinds of research that the company denies conducting—a difference without a distinction?

Source: https://www.dailysignal.com/2023/02/06/congress-must-demand-clarity-from-pfizer-execs-on-covid-19-viral-mutation-experiments/?utm_source=rss&utm_medium=rss&utm_campaign=congress-must-demand-clarity-from-pfizer-execs-on-covid-19-viral-mutation-experiments

Jackson said in a statement to Breitbart News, “Pfizer’s response to me was woefully inadequate and continues to show that big pharma is prioritizing its profits over the safety of the American public.

Source: https://www.breitbart.com/politics/2023/02/24/exclusive-rep-ronny-jackson-blasts-pfizer-denial-of-gain-of-function-accusations-as-woefully-inadequate/

Pfizer’s once-a-day version of danuglipron will likely take time to develop, while Lilly has moved its daily drug to late-stage trials, JPMorgan analysts led by Chris Schott wrote in a note.

Source: https://time.com/6290227/pfizer-shares-drop-after-lotiglipron-pause/

Pfizer’s revenue for the quarter was down 28.8% compared to the same quarter last year.

Source: https://www.americanbankingnews.com/2023/06/30/assenagon-asset-management-s-a-acquires-3689877-shares-of-pfizer-inc-nysepfe.html

The authorization was broader than Pfizer’s own request, which was to approve the dose for people aged 65 and above.

Source: https://dailycaller.com/2023/01/23/fda-annual-covid-vaccine-proposal/

The bottom line is that Pfizer’s Covid-19 success gave it a huge revenue boost, as well as the tools it is using to find more revenue as Covid-19 fades from memory.

Source: https://investorplace.com/2023/03/3-vaccine-stocks-to-watch-for-their-post-pandemic-moves/

The CDC’s recent endorsement of Pfizer’s maternal vaccine for respiratory syncytial virus is poised to make a profound impact on maternal and child healthcare.

Source: https://www.chiangraitimes.com/news/cdcs-independent-vaccine-advisers-recommend-maternal-vaccine-to-protect-infants-from-rsv/

While 2019 saw a pullback as COVID gripped the world, Q3 2021 to Q4 2022 earnings consistently rose above $20 billion per quarter as vaccines and then Paxlovid padded Pfizer’s bottom line and EPS.

Source: https://seekingalpha.com/article/4576684-pandemic-profits-in-healthcare?source=feed_all_articles

While some of its peers look to buy back stock now that their valuations have returned to earth, Pfizer’s invested, and pipelines are the be-all-end-all for pharmaceutical stocks.

Source: https://investorplace.com/2023/05/3-high-reward-stocks-riding-the-healthcare-boom/